Catégorie : Communiqué de presse

GlycoNet releases its 2022-2023 Corporate Report

Posted on |

GlycoNet releases its 2022-2023 Corporate Report

The report encapsulates a comprehensive overview of the network’s achievements, breakthroughs, and collaborations in the field of glycomics throughout the past year.

Within the report, readers will gain insight into the cutting-edge research and advancements made by GlycoNet, a collaborative effort involving scientists, researchers, and experts from academia, industry, and government institutions. It delves into the pioneering discoveries in glycobiology, highlighting the innovative applications and technologies that have emerged within the network.

Senator Paula Simons gets the sweet scoop on GlycoNet and glycomics

Posted on |

Senator Paula Simons gets the sweet scoop on GlycoNet and glycomics

Senator Paula Simons recently toured GlycoNet at the University of Alberta, exploring the realm of glycomics. The visit highlighted GlycoNet’s pivotal role in advancing glycomics and its transformative impact across One Health domains, underlined by discussions with GlycoNet’s CEO, Dr. Elizabeth Nanak.

The tour of cutting-edge labs showcased passionate researchers driving innovation in glycomics, and interactions with start-ups like 48Hour Discovery shed light on drug discovery advancements. This visit emphasized the value of such engagements, illustrating the shared commitment to a thriving future and the potential for collaborative efforts to elevate healthcare and nurture a diverse bioeconomy.

A Tour of the GlycoNet facilities with the Honourable Randy Boissonnault

Posted on |

A Tour of the GlycoNet facilities with the Honourable Randy Boissonnault

A significant gathering of researchers, industry experts, and rising stars in glycomics recently took place in Edmonton, Alberta with the Honourable Randy Boissonnault, focusing on advancements and current trends in the field.

PlantForm and UBC researcher receive GlycoNet funds to develop novel treatment for Type-2 diabetes

Posted on |

PlantForm and UBC researcher receive GlycoNet funds to develop novel treatment for Type-2 diabetes

PlantForm Corporation has teamed up with a University of British Columbia research group led by Dr. Joerg Bohlmann to develop a novel plant-based treatment option for Type-2 diabetes and obesity, with support from GlycoNet.

GlycoNet start-up GlyCa Biosciences Inc. and Huron Innovation Inc. partner to improve prostate cancer detection

Posted on |

GlycoNet start-up GlyCa Biosciences Inc. and Huron Innovation Inc. partner to improve prostate cancer detection

This partnership will launch the clinical trial of a new blood test to perfect early detection and diagnosis of clinically significant prostate cancer.

GlycoNet Integrated Services awarded $10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund

Posted on |

GlycoNet Integrated Services awarded $10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund

Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.

GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions

Posted on |

GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions

Glycomics is an integral part of ABOzymes’ life-saving research and technology development.

GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen

Posted on |

GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen

This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.

fr_CAFrench
en_USEnglish fr_CAFrench
Scroll to Top